[A21-01] Secukinumab (psoriatic arthritis) - Addendum to Commission A20-80
Last updated 18.02.2021
Project no.:
A21-01
Commission:
Commission awarded on 12.01.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Indication:
Adults with active psoriatic arthritis who responded inadequately to DMARD therapy
Result of dossier assessment:
Conclusion of dossier assessment A20-80 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-80 | Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-02-18: A G-BA decision was published.